{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:09:54Z","timestamp":1790021394234,"version":"4.0.1"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"02","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nIntroduction Conventional treatment guidelines of schizophrenia do not necessarily provide solutions on clinically important issues.<\/jats:p><jats:p>\nMethods A total of 141 certified psychiatrists of the Japanese Society of Clinical Neuropsychopharmacology evaluated treatment options regarding 19 clinically relevant situations in the treatment of schizophrenia with a 9-point scale (1=\u201cdisagree\u201d and 9=\u201cagree\u201d).<\/jats:p><jats:p>\nResults First-line antipsychotics varied depending on predominant symptoms: risperidone (mean\u00b1standard deviation score, 7.9\u00b11.4), olanzapine (7.5\u00b11.6), and aripiprazole (6.9\u00b11.9) were more likely selected for positive symptoms; aripiprazole (7.6\u00b11.6) for negative symptoms; aripiprazole (7.3\u00b11.9), olanzapine (7.2\u00b11.9), and quetiapine (6.9\u00b11.9) for depression and anxiety; and olanzapine (7.9\u00b11.5) and risperidone (7.5\u00b11.5) for excitement and aggression. While only aripiprazole was categorized as a first-line treatment for relapse prevention (7.6\u00b11.0) in patients without noticeable symptoms, aripiprazole (8.0\u00b11.6) and brexpiprazole (6.9\u00b12.3) were categorized as such for social integration. First-line treatments in patients who are vulnerable to extrapyramidal symptoms include quetiapine (7.5\u00b12.0) and aripiprazole (6.9\u00b12.1).<\/jats:p><jats:p>\nDiscussion These clinical recommendations represent the expert consensus on the use of a particular antipsychotic medication for a particular situation, filling a current gap in the literature.<\/jats:p>","DOI":"10.1055\/a-1324-3517","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T23:47:10Z","timestamp":1610495230000},"page":"60-67","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus"],"prefix":"10.1055","volume":"54","author":[{"given":"Hitoshi","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA"},{"name":"Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Yasui-Furukori","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, University of Yamanashi Faculty of Medicine, Yamanashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Psychiatry & Behavioral Science, Juntendo University Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Inada","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Tokyo Women\u2019s Medical University School of Medicine, Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka Sugawara","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Akita University School of Medicine, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Katsuki","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Occupational and Environmental Health, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Kishida","sequence":"additional","affiliation":[{"name":"Fujisawa Hospital, Kanagawa, Japan"},{"name":"Department of Psychiatry, Yokohama City University School of Medicine, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"A Hasan","year":"2012","journal-title":"World J Biol Psychiatry"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects","volume":"14","author":"A Hasan","year":"2013","journal-title":"World J Biol Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/15622975.2015.1009163","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation","volume":"16","author":"A Hasan","year":"2015","journal-title":"World J Biol Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"C Galletly","year":"2016","journal-title":"Aust NZ J Psychiatry"},{"key":"ref5","first-page":"71","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"2010","author":"R W Buchanan","journal-title":"Schizophr Bull"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"T R Barnes","year":"2020","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/HRP.0b013e31827fd915","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: An update on schizophrenia","volume":"21","author":"D N Osser","year":"2013","journal-title":"Harv Rev Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jad.2020.01.149","article-title":"Pharmacological management of depression: Japanese expert consensus","volume":"266","author":"H Sakurai","year":"2020","journal-title":"J Affect Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12959","article-title":"Pharmacological management of bipolar disorder: Japanese expert consensus","author":"H Sakurai","year":"2020","journal-title":"Bipolar Disord"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00131746-200301000-00004","article-title":"Treatment of behavioral emergencies: a summary of the expert consensus guidelines","volume":"9","author":"M H Allen","year":"2003","journal-title":"J Psychiatr Pract"},{"key":"ref13","first-page":"434","article-title":"Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: Meta-analysis. Br J Psychiatry","volume":"196","author":"N A Crossley","year":"2010","journal-title":"J Ment Sci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1017\/S1461145712001277","article-title":"Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: A systematic review and meta-analysis","volume":"16","author":"J-P Zhang","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/2045125318795130","article-title":"First-generation versus second-generation long-acting injectable antipsychotic drugs and time to relapse","volume":"8","author":"J M Stone","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/bjpo.bp.115.002576","article-title":"Long-term antipsychotic treatment in schizophrenia: Systematic review and network meta-analysis of randomised controlled trials","volume":"2","author":"Y J Zhao","year":"2016","journal-title":"BJPsych Open"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.schres.2015.07.007","article-title":"Qualify: A randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia","volume":"168","author":"D Naber","year":"2015","journal-title":"Schizophr Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/17425247.2016.1115479","article-title":"A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: A narrative review and critical appraisal","volume":"13","author":"T Suzuki","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis","volume":"394","author":"M Huhn","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4068\/cmj.2016.52.3.159","article-title":"Second generation antipsychotics in the treatment of major depressive disorder: an update","volume":"52","author":"S-M Wang","year":"2016","journal-title":"Chonnam Med J."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.euroneuro.2018.09.007","article-title":"Antipsychotic drugs for elderly patients with schizophrenia: A systematic review and meta-analysis","volume":"28","author":"M Krause","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref22","first-page":"CD006569","article-title":"Aripiprazole versus other atypical antipsychotics for schizophrenia","volume":"1","author":"P Khanna","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: A state-of-the-art clinical review","volume":"13","author":"M Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"ref24","volume-title":"Evidence-based medicine: How to practice and teach EBM","author":"D L Sackett","year":"2000","edition":"2nd ed."},{"key":"ref25","first-page":"945","article-title":"Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): A pragmatic, rater-blind, semi-randomised trial. Lancet","volume":"7","author":"E Johnsen","year":"2020","journal-title":"Psychiatry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2215-0366(18)30177-9","article-title":"Second-generation antipsychotic drugs and short-term mortality: A systematic review and meta-analysis of placebo-controlled randomised controlled trials","volume":"5","author":"J Schneider-Thoma","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00023210-200216040-00004","article-title":"Advances in atypical antipsychotics for the treatment of schizophrenia: New formulations and new agents","volume":"16","author":"J P Kelleher","year":"2002","journal-title":"CNS Drugs"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/YIC.0b013e328362db99","article-title":"Absence of evidence that the pro re nata regimen confers benefit: a review of the studies","volume":"28","author":"K Yoshida","year":"2013","journal-title":"Int Clin Psychopharmacol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s11920-014-0510-8","article-title":"Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature","volume":"16","author":"T M Fonseka","year":"2014","journal-title":"Curr Psychiatry Rep"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00406-018-0966-3","article-title":"Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: A population-based study","volume":"270","author":"A Panes","year":"2020","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40263-016-0311-1","article-title":"Worldwide differences in regulations of clozapine use","volume":"30","author":"J Nielsen","year":"2016","journal-title":"CNS Drugs"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/JCP.0000000000000932","article-title":"Psychopharmacology in Japan: An overview and recent topics","volume":"38","author":"K Yoshida","year":"2018","journal-title":"J Clin Psychopharmacol"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1324-3517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T23:49:39Z","timestamp":1615420179000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1324-3517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":30,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2021,3,10]]},"published-print":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1324-3517","relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]}}}